The safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma
Our study showed a safety profile comparable to that of CM648 trial. Nivo + Ipi as 2nd or later-line treatment demonstrated promising efficacy.
Authors
- Daisuke Kurita (ORCID: https://orcid.org/0000-0002-4243-3969)
- Junya Oguma (ORCID: https://orcid.org/0000-0002-3865-0514)
- Hiroshi Imazeki
- Yuri Yoshinami
- Mai Itoyama
- Yasuyuki Seto (ORCID: https://orcid.org/0000-0002-6953-8752)
- Hiroshi Igaki (ORCID: https://orcid.org/0000-0001-7817-624X)
- Kazuki Yokoyama
- Yoshitaka Honma (ORCID: https://orcid.org/0000-0002-4209-4493)
- Nozomu Ogura
- Ken Kato (ORCID: https://orcid.org/0000-0002-1733-5072)
- Hiroyuki Daiko (ORCID: https://orcid.org/0000-0002-9562-2966)
- Tairo Kashihara (ORCID: https://orcid.org/0000-0002-2471-605X)
- Koshiro Ishiyama
- Shun Yamamoto
- Kazuhiro Shiraishi (ORCID: https://orcid.org/0009-0004-3131-1829)
Institutions
- National Cancer Center (US)
- Tokyo National Hospital (JP)
Publication Details
- Journal
- Esophagus
- Published
- 2025-10-26
- DOI
- https://doi.org/10.1007/s10388-025-01162-3
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05